- 2024.12.26SSSRI Drug Price Database
Addition of the “Price Maintenance Premium (PMP)” and
Deductible information and Revision of Annual Fees - 2024.01.30Analysis of the prevalence of digital therapeutics (DTx) among physicians and the expectations they have
--PatientsMap 2023 Japan version— - 2023.10.25PatientsMap 2023 Japan version is now available
- 2023.02.02PatientsMap 2022 US version now available
- 2022.11.11PatientsMap 2022 Japan version now available
- 2022.08.25Analysis by scale of hospitals and cities by the top 10 companies in China in terms of sales rep activities (6 foreign-funded and 4 domestic-funded).
- 2022.06.28PatientsMap 2022 Japan Survey Begins.
- 2022.06.09PatientsMap analysis of Chinese physicians’ needs for new drugs
- 2022.04.22Launch of PatientsMap China 2022
- 2022.02.28Analysis of trends in the needs for new drugs with PatientsMap data
- 2021.03.05Increase in symptoms of depression and anxiety worldwide due to COVID-19
- 2017.12.07Launch of PatientsMap 2017 JP
- 2017.07.24Market Potential with new product needs in USA
- 2016.09.06China’s COPD market research report – now available
- 2015.08.21We welcome HIMA as an SSRI group company
- 2015.08.04Top unmet medical need: Obesity (US) vs. Dementia (Japan)
